Form 4: VTV Therapeutics Director Anne M. Phillips Acquires Stock Options

Director Anne M. Phillips acquired stock options in VTV Therapeutics Inc. following shareholder approval of the 2024 Equity Incentive Plan.

Summary

• On March 13, 2024, Anne M. Phillips, a director of vTv Therapeutics Inc., was granted stock options to purchase 3,750 shares of Class A Common Stock at an exercise price of $16.04 per share.
• The options vest in monthly installments over a three-year period starting March 13, 2024.
• The grant was conditional upon shareholder approval of the 2024 Equity Incentive Plan, which was obtained on June 11, 2024.
• The reporting person directly owns 3,750 derivative securities following the reported transaction.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction (stock option grant) following shareholder approval, indicating a neutral to slightly positive sentiment as it aligns director interests with company performance.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the company's long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies like BioCryst Pharmaceuticals or Ligand Pharmaceuticals also utilize stock options as part of their compensation strategy.
• The vesting schedule and exercise price are typical for similar grants in the sector.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
• Employees may see it as a positive sign of the company's commitment to its leadership.

Key Dates